Ban on drug advertising related with PPA ingredient

Published: 2000-11-20 11:53:00

Updated: 2000-11-20 11:53:00

The KPMA's Preview Committee for Pharmaceutical Advertising notified all member companies not to do any drug advertising by quoting PPA (Phenylpropanolamine: a sympathomimetic agent) ingredient, which is found in dozens of remedies and is linked to very rare cases of strokes in adults, particular...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK